Replies to post #203557 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Indeed and Marco Checchi is the Chief Science Officer of Neuronetrix Solutions, LLC.

Anavex is the applicant and Assignee with Marco Checchi as the inventor of this patent.

So Anavex owns the patent, which essentially claims a specific application of the Cognision device in the diagnosis and monitoring of treatment effectiveness using a certain dosing scheme of A2-73.

The good news is that after some back and forth the patent is now allowed, which should lead to a grant in due course.

07-17-2019 NOA Notice of Allowance and Fees Due (PTOL-85)

I haven't checked, but I guess Checchi owns other patents that in general protects the Cognision device. Perhaps other patent applications are being filed with Anavex and/or other biotechs for specific drugs and indications.

[Talon38]

JJ......the Consortium is quite an interesting grouping around the Neuronetrix ERP concept. On one end are Anavex and Cadent with no approved drugs but, intriguing and novel science for CNS and antipsychotic applications. Then there are Alkermers and Sage just beginning to bring to market the first of their drugs. And finally there are giants Lundbeck, Takeda and Merck covering Europe, Asia and the United States with mature pipelines and drugs on the market for CNS and Psychotic diseases. They all are interested in the ERP biomarker process, And, I daresay they are interested in what each one of them brings to the table. Suggest going on line to the companies website and see what they are into.....there is already collaboration in place. Did you know the original German Company, Merck, originated in the 1600's and that Lundbeck was a Danish hardware company originally.